Enzolytics Inc (ENZC)

[falon]

darron427,

You come on ENZC message board saying you can't verify information about the company. Then you bring up a lot of OLD information about the company that has nothing to do with what the company is doing today. We investor all well aware of the ENZC's past and horrible business decisions. That was then and this is now.

PS.. This "lab" Where this business was supposed to be operating out of when it kicked up in 2018 ( I believe it was) is also in photographs..

You want verification from some government well quite frankly I do too and I'm sure so do many investors in ENZC.

The situation is this:

ENZC is going the the required protocols and processes to bring their disruptive technology to the marketplace.

The information you want and trying to get on a message board is not going to happen because it does exist on message boards and you will never see some of the science behind ENZC claims because it is proprietary information.

So you can continue to play nice and think you are our saving us from something or you can move on as WE KNOW WHAT WE OWN and nobody is going to move us off the ENZC rock.

I specifically asked for some statement or science rendered by ENZC to the public stating they were developing a treatment or cure for COVID and AIDS.. Is that possible? Likely not since no one has TO DATE produced such dialogue from the mouths of ENZC corporate or research. Thanks again

I know. All tall tales ultimately lead back to this board from what I've seen. Anything I google about it, when I click it or follow it arounds the internet, the tales about an AIDS and COVID cure seemingly start right here with the hostest with the mostest.

This board did't create ENZC or the massive information that is available about it. We just break it down and share it.

REALLY try this link about Dr. Anthony Fauci connection to ENZC:

https://aumag.org/2013/09/26/the-future-of-clone-3/

Stranger still—in 1999, the government had made a patent application that overlapped an area covered by Dr. Cotropia’s 1989 patents. The government listed NIAID director Anthony Fauci and others as the “inventors.” In the affidavit required by the filing process, Fauci, et al., declared under oath that the neutralizing technology in question had “utility” and “commercial value.” But the U.S. Patent Examiner threw out the government’s bid to own the key area covering Clone 3. He pointed out that Dr. Cotropia and BioClonetics had a prior claim.

Then, in August 2010, came another landmark for Clone 3. The U.S. government’s Los Alamos HIV Clinical Database published a review of Clone 3 antibody’s capacity to bind directly with the 2,229 (then) known strains of HIV around the world. By searching the surface (amino acid) composition of these 2,229 HIV isolates, Los Alamos found that ninety-eight percent of them have an exact match—or conservative amino-acid substitution—for the minimal essential “core” epitope KLIC to which the CLONE 3 antibody binds. In other words, Clone 3 epitope KLIC has the potential to elicit, in active vaccination, a protective antibody (“CLONE 3”) that broadly neutralizes ninety-eight percent of all known HIV strains. This is more than any other vaccine candidate whose study results have been published.

The procedure for producing monoclonal antibodies is also significant and our procedure differs from those used by other pharma companies. In some cases, other pharma companies produce "humanized" rat and mouse monoclonal antibodies where the original antibody affinity and specificity are not maintained, and the chances of immunogenicity are increased. Our methodology also differs significantly from other pharma approaches using the transgenic mouse model a human immune system which has been "grafted" within a mouse model] having been "vaccinated" with specific and selected purified CoronaVirus Proteins.

In contrast, our model starts with human "immune-B cells", obtained from convalescent individuals who have recovered from the CoronaVirus. The primary distinction of our process for creating fully human monoclonals is the starting point - namely from human "immune-B cells" from humans who have survived successfully from a "natural" CoronaVirus infection. From these, we then produce antibodies that target conserved immutable sites on the virus - to avoid "virus escape".

Additionally, our antibodies retain the original natural antibody affinity and specificity and have lower risk of immunogenicity when used as a therapeutic. They will provide broad-spectrum coverage against viral variants with increased potency, stability as a single-domain molecule, and, in the recombinant form, will have accessibility to the virus epitopes (binding sites) not accessible with a whole antibody.
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-Shares-Current-BioClonetics-Immunotherapeutics-Inc-Update?id=280113

PLANO, TX / ACCESSWIRE / December 14, 2020 / Enzolytics, Inc. (OTC:ENZC, Company", )) has engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement ("MSA"), to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tested the compound in successful Clinical Trials in Bulgaria, but FDA regulations require separate Toxicity tests before an Investigational New Drug process may begin in the United States. https://marketwirenews.com/news-releases/enzolytics-inc-engages-bts-research-to-conduct-toxic-6758170663840334.html

COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today announced it has identified seven additional conserved, expectedly immutable sites on the HIV virus against which it plans to produce targeted anti-HIV monoclonal antibodies. The Company's primary anti-HIV monoclonal antibody targets one conserved site on the HIV virus, which site is 98% conserved (either directly or by way of conservative amino acid substitutions) over all 87,336 HIV isolates which have now been curated (analyzed) by the Company using Artificial Intelligence (AI). Additional conserved target sites (some with 98% conserved sequences) have now been identified against which fully human anti-HIV monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University's Institute for Preclinical Studies. The significance of producing multiple monoclonal antibodies targeting multiple conserved sites is recognized by experts as a critical approach to effective therapy. This allows the administration of a "cocktail" of antibodies, all targeting conserved and expectedly immutable sites.
The Company is also applying Artificial Intelligence [AI] to scan the hundreds of thousands of isolates that exist in 14 other prevalent viruses, ranging from influenza to Rabies to Ebola. Using the Company's proprietary technique for producing fully human monoclonal antibodies directed against these infectious diseases, the Company will produce multiple neutralizing monoclonal antibodies against these viruses. The significance of this approach is well recognized by experts in virology due to the ability of all viruses to mutate and render ineffective initially developed therapeutics.
Production of the Company's primary anti-HIV monoclonal antibodies is underway at Genscript Labs. Testing of these newly produced monoclonal antibodies is scheduled for early 2021 at the University of Strasbourg in Strasbourg France. Thereafter, Macaque trials are planned at the California National Primate Research Center, Univ. of California, Davis, CA.
Additional information on the progress and Company facilities will be part of the new Company website expected to be rolled out in the coming days.

CEO Charles Cotropia stated, "The Company is making significant progress on both of its therapeutic platforms: first, on the identification of prime target sites on both the CoronaVirus and the HIV virus and the creation of neutralizing antibodies directed against these sites, and second, on advancing its ITV-1 peptide therapeutic for patient application in the EU."

CSO Harry Zhabilov stated, "With the Bulgarian Drug Administration joining the European Medicine Agency and being recognized under the Mutual Recognition Agreement with the FDA, once we have successfully finished the permitting process the Company will be able to pursue FDA approval for ITV-1. We are currently investigating the required steps but feel confident that this is a viable option for the ITV-1 patented therapy."

https://marketwirenews.com/news-releases/enzolytics-announces-the-discovery-of-seven-newly-id-7491922242125190.html

ENZC have accomplished many milestones to get their products to the marketplace. We come a long way in a short period of time however much more work is necessary and unforeseen circumstances to overcome such as the situation in Bulgaria. Getting our first product to the marketplace is a priority as it is needed and will be done as soon as possible. Whether that is weeks or months away is not only up to the company but also any requirements set forth by regulatory agencies as we have seen with the toxicity test. ENZC is fortunate to be at the The Texas A&M Institute for Preclinical Studies (TIPS)

The link below has all ENZC Press Releases:
https://marketwirenews.com/stock/enzc/news/